Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 23, 2022 16:02 ET
|
Allogene Therapeutics, Inc.
AlloCAR T™ Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022Phase 1 Data from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma...
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
February 16, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
January 26, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
January 11, 2022 08:00 ET
|
Allogene Therapeutics, Inc.
miCAR Platform Enables Simultaneous Silencing of Multiple Gene TargetsAllogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products SOUTH SAN FRANCISCO,...
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
January 10, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Investigation Confirmed the Chromosomal Abnormality in a Single Patient was Not Observed in Any AlloCAR T Product and Not Related to Allogene Manufacturing Process or TALEN® Gene EditingClinical...
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
December 15, 2021 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
December 13, 2021 11:00 ET
|
Allogene Therapeutics, Inc.
ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate Responses Similar to Approved Autologous...
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
December 13, 2021 10:30 ET
|
Allogene Therapeutics, Inc.
ALPHA Trials Demonstrate Potential for AlloCAR T™ Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve PatientsAlloCAR T Therapy was Associated with Consistent and...
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
December 01, 2021 08:30 ET
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...